Stay updated on CTX130 in Relapsed/Refractory T/B Malignancies Clinical Trial
Sign up to get notified when there's something new on the CTX130 in Relapsed/Refractory T/B Malignancies Clinical Trial page.

Latest updates to the CTX130 in Relapsed/Refractory T/B Malignancies Clinical Trial page
- Check5 days agoChange DetectedRevision: v3.3.4 was added and Revision: v3.3.3 was removed as a minor site revision update. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedIntroduced a Locations section listing study sites in California, Connecticut, Florida, New York, Texas, Utah, New South Wales, and Ontario, reorganizing location details under a single header. The page revision is updated to v3.3.3.SummaryDifference1%

- Check48 days agoChange DetectedThe page now shows a new revision label 'Revision: v3.3.2', replacing the previous 'v3.3.1'. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check55 days agoChange DetectedPublications section now notes that articles are auto-filled from PubMed, and the page revision is updated to v3.3.1 (from v3.2.0).SummaryDifference0.1%

- Check62 days agoChange DetectedThe notice about a lapse in government funding and NIH operating status at the top of the page has been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check76 days agoChange DetectedNo significant content changes detected between the old and new page; core study details, eligibility criteria, outcomes, and locations appear unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

Stay in the know with updates to CTX130 in Relapsed/Refractory T/B Malignancies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CTX130 in Relapsed/Refractory T/B Malignancies Clinical Trial page.